Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical ...

Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...

DALLAS, TX, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) ...

AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...

Jan 29 (Reuters) - Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on ...

Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its ...

The use of AI in pharmaceutical development is becoming widespread, but the rulebook is still being written.McKinsey reports that 71% of businesses across various industries now use generative AI, ...

SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...